偷窥 性别 瘾 xxxxx,声声奶酥1v办公室,性色av蜜桃av人妻无码,欧洲精品99毛片免费高清观看

加入收藏 | 設(shè)為首頁 | 聯(lián)系我們

產(chǎn)品搜索

產(chǎn)品分類

聯(lián)系我們

聯(lián)系人:蔣經(jīng)理
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com

產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73196KIF5B(E15)-RET(E12) V804M/BaF3

KIF5B(E15)-RET(E12) V804M/BaF3
名稱 KIF5B(E15)-RET(E12) V804M/BaF3
型號(hào) CBP73196
報(bào)價(jià)
特點(diǎn) KIF5B(E15)-RET(E12) [V804M]/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO
  • 詳細(xì)內(nèi)容
CBP73196
I. Introduction

Cell Line Name:

KIF5B(E15)-RET(E12) [V804M]/BaF3

Host Cell:

BA/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RRPMI-1640+10%FBS

Mycoplasma Status:

Negative


II.Background

Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer (NSCLC). These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468. They are typically identified in young patients with adenocarcinoma histology and minimal smoking history. Therapeutic targeting of RET-fusion–driven NSCLCs has taken the form of treatment with broad-spectrum tyrosine kinase inhibitors with anti-RET activity, such as cabozantinib (Cabometyx; Cometriq), vandetanib (Caprelsa), lenvatinib (Lenvima), RXDX-105, and sunitinib (Sutent). Cabozantinib and vandetanib have been the most heavily studied multi-kinase inhibitors (MKIs), with response rates of 20% to 50% in largely pretreated patients with RET-rearranged NSCLC. Sunitinib has been used in fewer patients to date with initial results demonstrating a 22% response rate. RXDX-105 has exhibited uniquely impressive response rates (75%) in patients with non–KIF5B-RET-fusion NSCLC, compared with 0% response in patients with KIF5B-RET-fusion–positive NSCLC. BLU-667 has demonstrated an objective response rate of 50% in patients with RET-fusion positive NSCLC, and LOXO-292 reported a 74% ORR in patients with RET-fusion positive NSCLC. Notably, RXDX-105, BLU- 667, and LOXO-292 have all demonstrated some central nervous system activity in these early phase trials. Future directions of RET inhibition in patients with RET-rearranged NSCLC include additional clinical validation of the next generation RET-selective inhibitors RXDX-105, BLU-667, and LOXO-292 and comparing multikinase inhibitors with RET-selective inhibitors to determine the optimal sequencing of RET-targeted therapies.


III. Representative Data

1. WB of  KIF5B-RET [V804M]/BaF3

CBP73196 WB.png


2. Sanger of KIF5B-RET [V804M]/BaF3

CBP73196 sanger1.png

CBP73196 sanger2.png


3. Anti-proliferation assay


CBP73196 fig.jpg

Figure 4. CTG Proliferation Assay of BaF3 KIF5B-Ret(S) V804M Cells (C1).




如果你對(duì)CBP73196KIF5B(E15)-RET(E12) V804M/BaF3感興趣,想了解更詳細(xì)的產(chǎn)品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產(chǎn)品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細(xì)地址:

  • 補(bǔ)充說明:

  • 驗(yàn)證碼:

    請(qǐng)輸入計(jì)算結(jié)果(填寫阿拉伯?dāng)?shù)字),如:三加四=7

化工儀器網(wǎng)

推薦收藏該企業(yè)網(wǎng)站
亚洲日本va中文字幕无码| 豪妇荡乳1一5潘金莲| 国产精品久久久久久久久久久| 色婷婷7777免费视频在线观看| 污调教贱乳打屁股扒开作文| 9制片厂制片传媒在线播放| 艳mu无删减在线观看免费无码| 真人做人试看60分钟免费视频| かしこまりました中文在线| 色噜噜狠狠色综合日日| 夜夜爽夜夜叫夜夜高潮漏水| 岳让我弄进去看a片| 两片大荫唇之间已经湿漉漉的一片| 工头搡老女人老妇女老熟女| 亚洲同性男男gv在线观看| 日本大尺度做爰呻吟| 欧美vivodeshd| china中国bingo视频| 老师好爽要尿了潮喷了视频高潮| 美国式禁忌| 强开少妇嫩苞又嫩又紧小说| cao死你好紧好爽好湿视频男男| 在线永久看片免费的视频| 欧美超级乱婬视频播放| 精品久久久久久久无码| 色偷偷人人澡久久超碰97位| 永久939W75W75W乳液| 国产愉拍av免费视频一区 | 欧美肥胖老妇做爰| 男大学生自慰勃起chinese| 试看20分钟做受| 合集lunjian美人挨cao| 国产精品视频在线观看| 老熟女重囗味hdxx70星空| 嗯啊小sao货奶头好硬视频| 亚洲 欧美 自拍 另类 日韩| 精品乱码一区二区三区四区| 国产av无码专区亚洲av| 欧美黑人xxxx高潮猛交| 天天躁夜夜躁狠狠躁2021| 日韩在线观看视频|